Philadelphia, Pennsylvania, 9 February 2021 – A team from global law firm Hogan Lovells has advised EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, on a US$115 million public offering of shares of its common stock. Cowen and Guggenheim Securities acted as joint book-running managers for the offering.
Among other uses, this capital raise sets the stage for EyePoint’s continued advancement of EYP-1901, its potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration, the leading cause of vision loss in people over 65.
The Hogan Lovells team was led by Philadelphia-based partner Steve Abrams and counsel Stephen Nicolai. They were assisted by partners Susan Lee (Washington, D.C.) and Bob Underwood (Boston), counsel Teresa Lavenue (Washington, D.C), and associates Gibby Wagner (Philadelphia) and Sally Gu (Washington, D.C.).
